IO Biotech Receives Nasdaq Delisting Notice for Failing Market Value Requirement

summarizeSummary

IO Biotech, Inc. received a notice from Nasdaq for failing to meet the minimum $50 million Market Value of Listed Securities (MVLS) requirement, initiating a 180-day period to regain compliance and avoid potential delisting.

check_boxKey Events

• Nasdaq Non-Compliance Notice

  IO Biotech received a notice from Nasdaq on February 12, 2026, indicating non-compliance with the continued listing requirement for a minimum $50 million Market Value of Listed Securities (MVLS).

• 180-Day Compliance Period

  The company has 180 calendar days, until August 11, 2026, to regain compliance by having its MVLS meet or exceed $50 million for at least ten consecutive business days.

• No Immediate Delisting

  The notice has no immediate effect on the listing of the company's common stock, which will continue to trade on the Nasdaq Global Select Market.

• Exacerbates Prior Concerns

  This delisting notice follows recent negative developments, including a significant global workforce reduction announced on January 30, 2026, and the company's exploration of strategic alternatives, as disclosed on January 21, 2026.

auto_awesomeAnalysis

This Nasdaq delisting notice for failing to meet the $50 million Market Value of Listed Securities (MVLS) requirement is a critical development for IO Biotech. It underscores the company's precarious financial position, following recent disclosures of a significant workforce reduction and the exploration of strategic alternatives. While there is a 180-day compliance period, the company's current market capitalization is substantially below the threshold, indicating a significant challenge to regain compliance. Failure to do so could lead to delisting, severely impacting the company's liquidity, investor confidence, and ability to raise capital, especially as it seeks strategic options.